{
    "root": "2af91a53-9d36-4415-b4f3-cd78b8ad36ad",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Methoxsalen"
    },
    "value": "20250311",
    "ingredients": [
        {
            "name": "METHOXSALEN",
            "code": "U4VJ29L7BQ"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "GLYCINE",
            "code": "TE7660XO1C"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "MEDIUM-CHAIN TRIGLYCERIDES",
            "code": "C9H2L21V7U"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "Photochemotherapy (Methoxsalen with long wave UVA radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy. Methoxsalen is intended to be administered only in conjunction with a schedule of controlled doses of long wave ultraviolet radiation.",
    "contraindications": "CAUTION: Methoxsalen Capsules, USP represents a new dose form of methoxsalen. This new dosage form of methoxsalen exhibits significantly greater bioavailability and earlier photosensitization onset time than previous methoxsalen dosage forms. Each patient should be evaluated by determining the minimum phototoxic dose (MPD) and phototoxic peak time after drug administration prior to onset of photochemotherapy with this dosage form. Human bioavailability studies have indicated the following drug dosage and administration directions are to be used as a guideline only.",
    "warningsAndPrecautions": "Methoxsalen Capsules, USP 10 mg is green color, oval shaped soft gelatin capsule imprinted with 'M10' containing no drug crystals and clear colorless to pale yellow liquid, each containing 10 mg of methoxsalen (8-methoxypsoralen).  It is packed in amber colored glass bottles as 50's count (NDC 64380-752-16). \n                  Store at 20° to 25 °C (68° to 77 °F); excursions permitted between 15 °C - 30 °C (59 °F - 86 °F). \n                  [See USP Controlled Room Temperature]\n                  \n                     Manufactured by:\n                  \n                  Strides Pharma Science Ltd.\n                  Bengaluru - 562106, India\n                  \n                     Distributed by:\n                  \n                  Strides Pharma Inc.\n                  East Brunswick, NJ 08816",
    "adverseReactions": "A.    Patients exhibiting idiosyncratic reactions to psoralen compounds.\n                  B.     Patients possessing a specific history of light sensitive disease states should not initiate methoxsalen therapy except under special circumstances. Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.\n                  C.     Patients with melanoma or with a history of melanoma.\n                  D.    Patients with invasive squamous cell carcinomas.\n                  E.     Patients with aphakia, because of the significantly increased risk of retinal damage due to the absence of lenses."
}